Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma
<p>Background: Achievement of the best initial response to induction regimen in multiple myeloma is a prognostic factor for disease outcome. The triplet regimen-bortezomib, lenalidomide, and dexamethasone, VRd, is the preferred induction regimen in newly diagnosed Multiple Myeloma (MM) due to...
I tiakina i:
| Ngā kaituhi matua: | , , |
|---|---|
| Hōputu: | Pukapuka |
| I whakaputaina: |
Global Journal of Cancer Therapy - Peertechz Publications,
2021-02-13.
|
| Ngā marau: | |
| Urunga tuihono: | Connect to this object online. |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ipurangi
Connect to this object online.3rd Floor Main Library
| Tau karanga: |
A1234.567 |
|---|---|
| Tārua 1 | Wātea |